# Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma

> **NCT01182610** · PHASE2 · TERMINATED · sponsor: **Accelerated Community Oncology Research Network** · enrollment: 1 (actual)

## Conditions studied

- Gastroesophageal Adenocarcinoma
- Adenocarcinoma of the Distal Esophagus
- Adenocarcinomas of the Gastroesophageal Junction
- Adenocarcinoma of the Proximal Stomach

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** 5FU

## Key facts

- **NCT ID:** NCT01182610
- **Lead sponsor:** Accelerated Community Oncology Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Safety concern in a similar trial enrolling the same patient population
- **Last updated:** 2012-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01182610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01182610, "Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01182610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*